Valion Bio, Inc.(VBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.8M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VBIO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Valion Bio, Inc. (VBIO), a Healthcare sector company. VBIO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.8m in revenue. Based on the latest XBRL financial filings (Q1 2026), Valion Bio, Inc. reports net income of $-6.2M, free cash flow of $-5.0M. Top institutional holders of VBIO by reported 13-F value include GEODE CAPITAL MANAGEMENT,, Sanctuary Advisors,, Marex Group plc, based on the most recent SEC filings. VBIO trades on the Nasdaq exchange and files with the SEC under CIK 1787740. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Valion Bio, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-6.2M
Free Cash Flow
Q1 2026
$-5.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-7.7% YoYOperating Income
+4.2% YoYEPS (Diluted)
Total Assets
+512.9% YoYOp. Cash Flow
+17.8% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|
| Revenue | — | $1.2M -36.1% | $1.8M | — |
| Net Income | $-8.9M -7.7% | $-8.2M +18.3% | $-10.1M | — |
| Operating Income | $-7.9M +4.2% | $-8.2M +18.4% | $-10.1M | — |
| EPS (Diluted) | — | $-10.40 -69.5% | $-6.14 | — |
| Total Assets | $31.6M +512.9% | $5.2M -11.9% | $5.9M | — |
| Operating Cash Flow | $-7.0M +17.8% | $-8.5M +4.6% | $-8.9M | — |
AI Insight: VBIO Financial Trends
Valion Bio is a pre-revenue biotech burning cash at an accelerating rate, with quarterly net losses reaching $6M in Q1 2026.
• Net income losses deteriorated from $1M per quarter in mid-2024 to $6M in Q1 2026, a 6× increase in cash burn.
• Operating cash burn widened from $1M in Q2–Q4 2024 to $5M in Q1 2026, signaling intensifying R&D or clinical spending.
• Equity swung from $3M–$4M in 2024 to $17M in Q4 2025, likely from capital raise, but eroded to $11M by Q1 2026 due to losses.
⚠ Runway unclear: at current $5M–$6M quarterly burn, Q1 2026 equity of $11M suggests <3 quarters of cash coverage.
⚠ No revenue generation visible across full 10-quarter window; clinical milestone or partnership timing critical to survival.
AI Insight: VBIO Ratio Trends
Valion Bio remains unprofitable with deteriorating returns; Q4 2025 showed modest ROIC improvement but ROA worsened in Q1 2026.
• ROE improved sharply from -197.9% in Q1 2025 to -67.8% in Q4 2025, though remains deeply negative.
• ROA deteriorated from -36.1% in Q4 2025 to -64.9% in Q1 2026, signaling declining asset efficiency.
• ROIC was -47.0% in Q4 2025; no capital is being productively deployed.
⚠ ROA gap widened between Q4 2025 (-36.1%) and Q1 2026 (-64.9%) — largest quarterly deterioration in available data.
⚠ Sustained negative profitability across all metrics; no path to positive returns evident in trend.
Get alerted when VBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Valion Bio, Inc. including:
Top Institutional Holders of VBIO
GEODE CAPITAL MANAGEMENT, LLC
$77.8K87,818 shSanctuary Advisors, LLC
$54.2K61,205 shMarex Group plc
$52.5K59,263 shXTX Topco Ltd
$9.3K10,506 shUBS Group AG
$2.1K2,366 shTower Research Capital LLC (TRC)
$517.00584 shHRT FINANCIAL LP
$37.0042,419 shSBI Securities Co., Ltd.
$14.0016 shCaitong International Asset Management Co., Ltd
$1.001 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $77.8K | 87,818 |
| Sanctuary Advisors, LLC | $54.2K | 61,205 |
| Marex Group plc | $52.5K | 59,263 |
| XTX Topco Ltd | $9.3K | 10,506 |
| UBS Group AG | $2.1K | 2,366 |
| Tower Research Capital LLC (TRC) | $517.00 | 584 |
| HRT FINANCIAL LP | $37.00 | 42,419 |
| SBI Securities Co., Ltd. | $14.00 | 16 |
| Caitong International Asset Management Co., Ltd | $1.00 | 1 |
More Healthcare Companies
View all Healthcare →Put VBIO on your watchlist
Track score changes the day Valion Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VBIO a good stock to buy?
13F Pro's AI-powered analysis of Valion Bio, Inc. (VBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VBIO are available on the VBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own VBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Valion Bio, Inc.'s investment landscape.